price
PC
NASDAQ · PCVX
Vaxcyte, Inc. Common Stock
Healthcare · Biotechnology
$60.37
Down-$2.24 (-3.71%)
Updated Sep 18, 2026, 10:01 PM
SID Score
6.2/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 5.84B
- P/E ratio
- -9.24
- Dividend yield
- 0.00%
- 52-week range
- $31.89 – $65.00
- Volume
- 1.31M
- Avg. volume
- 1.73M
Price performance
PCVX price history
1M range · 20 trading sessions · Daily adjusted prices
PCVX closed at $60.37 after 20 trading sessions, down 1.58% for the selected period.
- Last close
- $60.37
- Period change
- -1.58%
- Period low
- $58.77
- Period high
- $62.62
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 17, 2026 | $60.22 | $61.50 | $59.31 | $60.37 | 1.31M |
| Sep 16, 2026 | $59.25 | $60.13 | $58.40 | $58.77 | 1.25M |
| Sep 15, 2026 | $59.70 | $59.75 | $58.185 | $59.21 | 1.89M |
| Sep 14, 2026 | $60.04 | $60.8547 | $59.085 | $59.54 | 1.43M |
| Sep 11, 2026 | $60.07 | $60.20 | $58.21 | $59.47 | 1.68M |
| Sep 10, 2026 | $59.19 | $60.13 | $58.555 | $58.90 | 1.16M |
| Sep 9, 2026 | $59.99 | $60.33 | $59.045 | $59.51 | 1.2M |
| Sep 8, 2026 | $60.25 | $61.03 | $59.22 | $60.36 | 1.02M |
| Sep 4, 2026 | $59.73 | $61.78 | $59.645 | $61.16 | 986.71K |
| Sep 3, 2026 | $61.73 | $62.14 | $59.85 | $61.17 | 736.47K |
| Sep 2, 2026 | $61.63 | $62.90 | $60.82 | $61.58 | 1.02M |
| Sep 1, 2026 | $60.29 | $62.14 | $60.06 | $60.81 | 1.44M |
| Aug 31, 2026 | $59.10 | $61.61 | $58.51 | $60.74 | 1.75M |
| Aug 28, 2026 | $61.06 | $62.375 | $59.485 | $59.835 | 760.16K |
| Aug 27, 2026 | $60.51 | $61.60 | $59.93 | $61.155 | 611.75K |
| Aug 26, 2026 | $61.035 | $61.645 | $60.32 | $61.09 | 891.7K |
| Aug 25, 2026 | $62.22 | $63.92 | $60.96 | $61.09 | 1.22M |
| Aug 24, 2026 | $62.30 | $63.05 | $61.23 | $61.87 | 662.14K |
| Aug 21, 2026 | $61.60 | $63.98 | $61.60 | $62.62 | 1.14M |
| Aug 20, 2026 | $62.23 | $62.91 | $60.80 | $61.34 | 726.44K |
Latest PCVX news
The latest Smart Investors Daily articles mentioning PCVX.
Stock researchCompany · Financials
Loading stock research…